Michael Stocum

In his 20-plus year industry career, Michael has made an impact on products across several therapeutic areas. He has held corporate roles in pharmaceuticals with GlaxoWellcome/GSK, biologics at Organon (now Merck/Schering-Plough) and molecular diagnostics at Organon Teknika (now bioMerieux) plus two biotech start-ups. His roles have spanned bench research to product, business and commercial development, impacting multiple innovative molecular diagnostics such as HIV-1 RNA and HBV DNA viral load tests along with numerous medicines in several disease areas including cancer (Onco-TICE BCG, Tykerb and Votrient), infectious diseases (abacavir) and cardiometabolic diseases (Avandia and darapladib). In 2004 Michael founded Personalized Medicine Partners to provide global strategic business and operational capabilities for biopharmaceutical, diagnostic and research/clinical services companies, specialising in the development and commercialisation of integrated therapeutic and biomarker/companion diagnostic programmes. Michael currently chairs the Personalized Medicine Division of the American Association for Clinical Chemistry and is active in the Personalized Medicine Coalition, a non-profit dedicated to advancing the field of Personalized Medicine. He also serves on the Industry Advisory Board for the Professional Science Masters program at NC State University (NCSU). Michael earned dual B.S. degrees in Biochemistry and Microbiology from North Carolina State University, with a minor in Genetics and an M.S. in Biotechnology Management, plus two years of academic research assistantships at NCSU and the National Institutes of Health.